Breaking News

BrainStorm, Catalent Complete Tech Transfer for NurOwn

Autologous cell therapy for the treatment of ALS and PMS will be manufactured at Catalent’s 32,000 sq.-ft. cell therapy manufacturing facility in Houston.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

BrainStorm Cell Therapeutics Inc., a developer of cell therapies for neurodegenerative diseases, and Catalent, a global CDMO, have completed the technology transfer for NurOwn manufacturing at Catalent’s facility. NurOwn is BrainStorm’s autologous cellular therapy being developed for the treatment of amyotrophic lateral sclerosis (ALS), progressive multiple sclerosis (PMS) and other neurodegenerative diseases.   Catalent entered into a partnership with Brainstorm in 2020 to provide cGMP clinic...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters